CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Emeritus professor honored for gas turbine research
August 17, 2026
Mark Turner has been part of the University of Cincinnati's College of Engineering and Applied Science for 25 years. His work in the field of gas turbine simulation and design continues to leave a significant impact on the industry. He was honored by the American Society of Mechanical Engineers with the International Gas Turbine Institute Scholar Award. Turner is part of the Department of Aerospace Engineering and Engineering Mechanics at UC.
UC expert offers advice to Cincinnati on climate change
August 14, 2026
In an op-ed, UC Associate Professor Bob Hyland talks about ways Cincinnati can become more resilient in face of climate change.
UC named a best employer in Ohio by Forbes
August 14, 2026
Forbes ranks the University of Cincinnati No. 24 on its 2026 America’s Best Employers By State list for Ohio, recognizing UC’s strong workplace culture and employee experience.